Online inquiry

IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13128MR)

This product GTTS-WQ13128MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ13128MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5224MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CB 2679d
GTTS-WQ5560MR IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDP-771
GTTS-WQ8936MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ8527MR IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Hu3F8
GTTS-WQ972MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-368
GTTS-WQ5782MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ6176MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CP-751871
GTTS-WQ11401MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI-575
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW